Form 4: Celldex Therapeutics SVP & General Counsel Acquires 75,000 Stock Options
SEC Form 4 Filing
Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, acquired 75,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.
Summary
- Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, filed a Form 4 with the SEC.
- The filing reports the acquisition of 75,000 incentive stock options on June 13, 2024, at an exercise price of $36.43.
- These options were granted under the company's 2021 Omnibus Equity Incentive Plan.
- The options vest 25% on June 13, 2025, and the remaining portion vests quarterly over the following 12 quarters.
- Following the transaction, Jimenez directly owns 75,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
- The vesting schedule of 25% after one year followed by quarterly vesting is a standard practice to incentivize long-term commitment.
Stakeholder Impact
- The stock option grant could positively impact shareholders by aligning management's interests with the company's long-term success.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the transaction (grant of stock options) |
| 06/13/2025 | Date when 25% of the options vest |
| 06/13/2034 | Expiration date of the options |
| 06/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.